Exicure (NASDAQ:XCUR) Trading Down 0.5% – Should You Sell?

Exicure, Inc. (NASDAQ:XCUR) shares traded down 0.5% on Monday . The company traded as low as $3.75 and last traded at $3.77. 8,315 shares traded hands during trading, a decline of 37% from the average session volume of 13,143 shares. The stock had previously closed at $3.79.

Wall Street Analysts Forecast Growth

XCUR has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Exicure in a research report on Monday, December 29th. Wall Street Zen upgraded Exicure to a “hold” rating in a research report on Saturday, January 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Exicure has a consensus rating of “Sell”.

Exicure Price Performance

The company has a fifty day moving average price of $4.05 and a two-hundred day moving average price of $4.68. The firm has a market cap of $24.01 million, a price-to-earnings ratio of -4.90 and a beta of 4.02.

Exicure (NASDAQ:XCUR) last released its earnings results on Wednesday, March 25th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($18.60) by $18.14.

About Exicure

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.